Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)

Junzo Hamanishi, Nobuhiro Takeshima, Noriyuki Katsumata, Kimio Ushijima, Tadashi Kimura, Satoshi Takeuchi, Koji Matsumoto, Kimihiko Ito, Masaki Mandai, Hidekatsu Nakai, Noriaki Sakuragi, Hidemichi Watari, Nobutaka Takahashi, Hidenori Kato, Kosei Hasegawa, Kan Yonemori, Mika Mizuno, Kazuhiro Takehara, Hitoshi Niikura, Takashi SawasakiSari Nakao, Toshiaki Saito, Takayuki Enomoto, Satoru Nagase, Nao Suzuki, Takashi Matsumoto, Eiji Kondo, Kenzo Sonoda, Satomi Aihara, Yoichi Aoki, Aikou Okamoto, Hirokuni Takano, Hiroshi Kobayashi, Hisamori Kato, Yoshito Terai, Akira Takazawa, Yusuke Takahashi, Yoshinobu Namba, Daisuke Aoki, Keiichi Fujiwara, Toru Sugiyama, Ikuo Konishi

Research output: Contribution to journal › Article › peer-review

47 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)'. Together they form a unique fingerprint.

Medicine & Life Sciences